Evidence map›Paper›PMID 40927764›Full record

ArticleMolecular therapy. Methods & clinical development2025

Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment.

Kazuto Yamazaki, Kenji Kubara, Go Sugahara, Hiroki Muto, Masae Yamamoto, Yuji Mano, Kaoru Mitsuhashi, Chihiro Yamasaki, Yuji Ishida, Chise Tateno and 1 more

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. High-Throughput Strategies for Streamlining Lipid Nanoparticle Development Pipeline.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kazuto YamazakiEisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Kenji KubaraEisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Go SugaharaResearch and Development Department, PhoenixBio Co., Ltd., 3-4-1, Kagamiyama, Higashi-Hiroshima, Hiroshima 739-0046, Japan.
Hiroki MutoEisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Masae YamamotoEisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Yuji ManoEisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Kaoru MitsuhashiEisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Chihiro YamasakiResearch and Development Department, PhoenixBio Co., Ltd., 3-4-1, Kagamiyama, Higashi-Hiroshima, Hiroshima 739-0046, Japan.
Yuji IshidaResearch and Development Department, PhoenixBio Co., Ltd., 3-4-1, Kagamiyama, Higashi-Hiroshima, Hiroshima 739-0046, Japan.
Chise TatenoResearch and Development Department, PhoenixBio Co., Ltd., 3-4-1, Kagamiyama, Higashi-Hiroshima, Hiroshima 739-0046, Japan.
Yuta SuzukiEisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver-humanized chimeric mice (PXB-mice) are widely utilized for predicting human pharmacokinetics (PK) and as human disease models. However, residual metabolic activity of mouse hepatocytes in chimeric mice can interfere with accurate human PK estimation. Lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) treatment makes it possible to eliminate the shortcomings of chimeras and create new models. Therefore, we aimed to create a new model in which siRNA for mouse cytochrome P450 oxidoreductase (

Indexed as

chimeric micecytochrome P450 oxidoreductasedrug metabolismhumanized liverslipid nanoparticlesiRNAspecies specificity

Identifiers

PMID40927764
PMCPMC12415978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.